Contact US

You have any questions or need to contact us about something? Reach out, we’d be happy to hear from you!

ask.pathinvestments@gmail.com

  • twitter
  • facebook
  • linkedin

All the Latest

Welcome to Path Investments

Please reload

Archive

Please reload

Tags

Our Recent Posts

Please reload

July 7, 2017

PARP inhibitors are a new class of drugs found to suppress the progression of certain cancers such as ovarian, in recurrent platinum-sensitive patients. Due to their initial success in treatment, research and development in the field has taken off and several new drugs have entered the market this year. Given their implications in the field of onco...

March 27, 2017

Allergan is an extremely diverse company spanning through many fields of medicine. It is well positioned to keep growing and has a very low single drug risk. Many of its newly introduced drugs are extremely useful to patients especially in the eye care and aesthetics segments and will continue to be adopted thoroughly and quickly. Allergan’s CEO ha...

March 20, 2017

If granted the NDA, Kite will the first to market for this disease and will immediately become a leading treatment option. Given the number of patients living with this disease, many need this drug immediately and will not be able to wait for further results from Juno’s JCAR 017 and potential approval. Kite’s has also raised an additional $409.7 mi...

February 23, 2017

Tesla's stock is purely valued for the company it could be and does not reflect the financial uncertainties and the extraordinary debt it carries underneath. Undoubtedly, Tesla can still go up from current price as traders become more excited about the Model 3 and other short term catalysts, but long term investors should stay put as there will...

February 9, 2017

Gilead's pipeline has a newly approved drug for treating HBV (Vemlidy) and phase 3 trials in NASH. Both these diseases represent huge opportunities for Gilead since there there are a vast number of patients and no reasonable treatment options in either. In 2017 I expect Gilead to proceed with M&A as well as activist investment into the company....

Please reload

 
 
 

©2017 by Path Investments.

  • twitter
  • facebook
  • linkedin